Sarizotan

Из Википедије, слободне енциклопедије
Sarizotan
Sarizotan.png
IUPAC ime
1-[(2R)-3,4-dihidro-2H-hromen-2-il]-N-([5-(4-fluorofenil)pyridin-3-il]metil)metanamin
Klinički podaci
Kategorija trudnoće
  • N/A
Način primene Oralno
Identifikatori
CAS broj 177975-08-5 ДаY
ATC kod none
PubChem CID 6918388
ChemSpider 2319847
UNII 467LU0UCUW ДаY
Hemijski podaci
Formula C22H21FN2O
Molarna masa 348,413 g/mol

Sarizotan (EMD-128,130) je selektivni agonist 5-HT1A receptor i antagonist D2 receptora,[1] sa antipsihotičkim dejstvom.[2][3] Takođe je poznato da redukuje diskineziju kod dugotrajnih tretmana Parkinsonove bolesti sa levodopom.[4][5][6][7]

Reference[уреди]

  1. Rabiner, E. A.; Gunn, R. N.; Wilkins, M. R.; Sedman, E.; Grasby, P. M. (2002). „Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with 11CWAY-100635 and 11Craclopride”. Journal of psychopharmacology (Oxford, England). 16 (3): 195—199. doi:10.1177/026988110201600301. PMID 12236624. }
  2. Assié, M.; Ravailhe, V.; Faucillon, V.; Newman-Tancredi, A. (2005). „Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain”. The Journal of Pharmacology and Experimental Therapeutics. 315 (1): 265—272. doi:10.1124/jpet.105.087163. PMID 15987834. 
  3. Auclair, A.; Galinier, A.; Besnard, J.; Newman-Tancredi, A.; Depoortère, R. (2007). „Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats”. Psychopharmacology. 193 (1): 45—54. doi:10.1007/s00213-007-0762-7. PMID 17393144. 
  4. Bibbiani, F.; Oh, J. D.; Chase, T. N. (2001). „Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models”. Neurology. 57 (10): 1829—1834. PMID 11723272. 
  5. Bartoszyk, G.; Van Amsterdam, C.; Greiner, H.; Rautenberg, W.; Russ, H.; Seyfried, C. (2004). „Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile”. Journal of neural transmission (Vienna, Austria : 1996). 111 (2): 113—126. doi:10.1007/s00702-003-0094-7. PMID 14767715. 
  6. Bara-Jimenez, W.; Bibbiani, F.; Morris, M.; Dimitrova, T.; Sherzai, A.; Mouradian, M.; Chase, T. (2005). „Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease”. Movement disorders : official journal of the Movement Disorder Society. 20 (8): 932—936. doi:10.1002/mds.20370. PMID 15791634. 
  7. Grégoire, L.; Samadi, P.; Graham, J.; Bédard, P.; Bartoszyk, G.; Di Paolo, T. (2009). „Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys”. Parkinsonism & related disorders. 15 (6): 445—452. doi:10.1016/j.parkreldis.2008.11.001. PMID 19196540. 

Vidi još[уреди]

Spoljašnje veze[уреди]